Coverage Reiterated: Apple (AAPL), Amazon.com (AMZN), Arris Group (ARRS), GlaxoSmithKline plc (GSK), Pharmacyclics (PCYC)

Apple Inc. (AAPL) was reiterated as ‘Outperform’ by RBC Capital Markets analysts on Thursday. The broker also increased its price target on the stock to $140 from $130.

Apple Inc., currently valued at $749.10 billion, has a median Wall Street price target of $135.00 with a high target of $165.00. Approximately 28 million shares have already changed hands, compared to the stock’s average daily volume of 55.47 million.

In the past 52 weeks, shares of the iPhone maker have traded between a low of $73.05 and a high of $129.03 with the 50-day MA and 200-day MA located at $115.02 and $107.54 levels, respectively. Additionally, shares of AAPL trade at a P/E ratio of 1.18 and have a Relative Strength Index (RSI) and MACD indicator of 75.18 and +5.69, respectively.

AAPL currently prints a one year return of 68.15%, and a year-to-date return of around 17%.

Amazon.com Inc. (AMZN) was reiterated as ‘Overweight’ with a $475 from $420 price target on Thursday by Piper Jaffray.

On valuation measures, Amazon.com Inc. shares have a PEG and forward P/E ratio of 36.43 and 166.14, respectively. Price/Sales for the same period is 1.95 while EPS is ($0.52). Currently there are 22 analysts that rate AMZN a ‘Buy’, 16 rate it a ‘Hold’. No analysts rate it a ‘Sell’. AMZN has a median Wall Street price target of $395.00 with a high target of $450.00.

In the past 52 weeks, shares of Seattle, Washington-based e-commerce giant have traded between a low of $284.00 and a high of $383.11 and are now at $380.40.

Shares are up 5.58% year-over-year, and 20.31% year-to-date.

Arris Group, Inc.‘s (ARRS) rating of ‘Buy’ was reiterated today at Brean Capital with a price target decrease of $34 from $36 (versus a $27.81 previous close).

Arris Group shares have gained 3.60% over the past 52 weeks, while the S&P 500 index has gained 14.13% in the same period.

ARRS recently traded at $28.95, up 4.10 percent.

Shares of GlaxoSmithKline plc (GSK) are down 0.78% in midday trading after Argus reiterated its ‘Buy’ rating and decreased its 12-month base case estimate on the name by three points to $52 a share.

GSK shares recently lost 40.39 to $46.91. In the past 52 weeks, shares of Brentford, UK-based company have traded between a low of $41.25 and a high of $56.60. Shares are down 10.77% year-over-year ; up 12.30% year-to-date.

Pharmacyclics Inc. (PCYC) was reiterated as ‘Buy’ and the price target was raised to $205 from $180 at Deutsche Bank (DB).

PCYC shares recently gained $0.61 to $170.82. The stock is up more than 22.27% year-over-year and has gained roughly 39.22% year-to-date. In the past 12 months, shares of Sunnyvale, California-based biopharmaceutical company have traded between a low of $82.51 and a high of $175.00.

Pharmacyclics Inc. closed Wednesday at $170.21. The name has a total market cap of $12.90B.

Be the first to comment

Leave a Reply

Your email address will not be published.


*